KNSA
KNSA clinical trials: Kiniksa Pharmaceuticals International, plc
Every trial on ClinicalTrials.gov where Kiniksa Pharmaceuticals International, plc is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 15
- Trials linked
- 10
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
KNSA on the catalyst calendar · KNSA registry changes
- Primary completion Dec 31, 2027Sponsor estimatePhase 2NCT07288216Transition to KPL-387 Monotherapy Dosing & Administration StudyKiniksa Pharmaceuticals International, plc · Recurrent PericarditisRecruitingKNSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2027Sponsor estimatePhase 2/Phase 3NCT07010159Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387Kiniksa Pharmaceuticals International, plc · PericarditisRecruitingKNSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimateNo phase registeredNCT04687358REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult PatientsKiniksa Pharmaceuticals International, plc · Recurrent PericarditisActive, not recruitingKNSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 8, 2024ActualPhase 2NCT05198310Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response...Kiniksa Pharmaceuticals, Ltd. · Arthritis, RheumatoidCompletedKNSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 6, 2025ActualPhase 2NCT06531395A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's DiseaseKiniksa Pharmaceuticals International, plc · Sjögrens DiseaseTerminatedKNSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 12, 2021ActualPhase 2/Phase 3NCT04447469Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and...Kiniksa Pharmaceuticals International, plc · COVIDCompletedKNSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 13, 2020ActualPhase 2NCT03827018KPL-301 for Subjects With Giant Cell ArteritisKiniksa Pharmaceuticals, Ltd. · Giant Cell ArteritisCompletedKNSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 29, 2020ActualPhase 3NCT03737110Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent PericarditisKiniksa Pharmaceuticals (UK), Ltd. · Recurrent PericarditisCompletedKNSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 17, 2019ActualPhase 2NCT03980522A Pilot Study of KPL-914 in Recurrent PericarditisKiniksa Pharmaceuticals (UK), Ltd. · Recurrent PericarditisCompletedKNSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 21, 2021ActualPhase 1NCT04497662Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy SubjectsKiniksa Pharmaceuticals, Ltd. · Healthy VolunteersCompletedKNSALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2022ActualPhase 2NCT03816891Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo NodularisGenentech, Inc. · Prurigo NodularisCompletedKNSACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 1, 2020ActualPhase 2NCT03858634A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic DiseasesGenentech, Inc. · Chronic Idiopathic UrticariaCompletedKNSACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 16, 2020ActualPhase 2NCT04492514Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationKristin Hudock · COVID 19CompletedKNSACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2020ActualPhase 2NCT04463004Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationVirginia Commonwealth University · COVID-19CompletedKNSACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 23, 2021ActualPhase 2NCT04399980Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationThe Cleveland Clinic · COVID 19CompletedKNSACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 15 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner